The immune checkpoint inhibitors targeting PD-1/PD-L1, after the relevant results in the treatment of advanced NSCLC, have also been tested in several clinical trials in adjuvant or neoadjuvant settings. Here, PDCD1 is linked to non-small cell lung carcinoma.